Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

doi:10.1056/NEJMoa2103695

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

The New England journal of medicine - 24 Jun 2021

Skoulidis Ferdinandos, Li Bob T, Dy Grace K, Price Timothy J, Falchook Gerald S, Wolf Jürgen, Italiano Antoine, Schuler Martin, Borghaei Hossein, Barlesi Fabrice, Kato Terufumi, Curioni-Fontecedro Alessandra, Sacher Adrian, Spira Alexander, Ramalingam Suresh S, Takahashi Toshiaki, Besse Benjamin, Anderson Abraham, Ang Agnes, Tran Qui, Mather Omar, Henary Haby, Ngarmchamnanrith Gataree, Friberg Gregory, Velcheti Vamsidhar, Govindan Ramaswamy

Abstract excerpt

BACKGROUND: Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC). METHODS: In a single-group, phase 2 trial, we investigated the activity of sotorasib, administered orally at a dose of 960 mg once daily, in patients with KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to Piperazines

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 34096690
DOI: 10.1056/NEJMoa2103695
PMCID: PMC9116274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.PMID 34096690Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read ↗

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].Semantic proximity Read ↗

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read ↗

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.Semantic proximity Read ↗

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.Semantic proximity Read ↗

Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer.Semantic proximity Read ↗

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.Semantic proximity Read ↗

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.